Trial · NCT01228214
Novel Treatment for Coronary Artery Disease
NCT01228214, Phase 2, Phase 3, Unknown, University of Carabobo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Novel Treatment for Coronary Artery Disease. Trials, record NCT01228214. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01228214
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Novel Treatment for Coronary Artery Disease
- NCT number
- NCT01228214
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 100 participants, actual
- Lead sponsor
- University of Carabobo
- Conditions
- Coronary Artery Disease
- Interventions
- Placebo, amiloride
- First posted
- 2010-10-26
- Last updated
- 2013-03-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Regression of Angina Without Recurrence | Baseline, 1, 3, 6 and 12 Months during the first year trial, and every 6-months in the 2nd year period | Evaluation of Angina Class according the Canadian Society of Cardiology (CCS) |
| Primary | Regression of ST-T and T-waves Alterations of Myocardial Ischemia | Baseline, 1, 3, 6 and 12 Months during the first year trial, and every 6-months in the 2nd year period | Evaluation according the Minnesota Code |
| Primary | RBC Potassium Content | Baseline, 1, 3, 6 and 12 Months during the first year trial, and every 6-months in the 2nd year period | Obtained by a novel accurate method developed in our laboratory (Nutr Metab Cardiovasc Dis. 2002 Jun;12(3):112-116 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01228214
GET https://conductscience.org/api/trials/v1/NCT01228214/registered